Patience needed at Merck & Co as IMPROVE-IT takes its time and triple CV combo is halted
13:05 EDT 10 Aug 2012 | SCRIP
Delays seem to be the order of the day for Merck & Co's cardiovascular franchise, with its latest form 10-Q filing revealing that the company has halted its development programme for MK-0524B and that the results of the long-awaited.....
Original Article: Patience needed at Merck & Co as IMPROVE-IT takes its time and triple CV combo is halted
More From BioPortfolio on "Patience needed at Merck & Co as IMPROVE-IT takes its time and triple CV combo is halted"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
